Trump's health in spotlight: Chronic venous insufficiency diagnosis explained
Leavitt emphasised that there was no indication of more serious conditions such as deep vein thrombosis, arterial disease, heart failure, or kidney issues. She added that Trump is not experiencing any discomfort due to the diagnosis.Leavitt: "I know that many in the media have been speculating about bruising on the president's hand and also swelling in the president's legs. In the effort of transparency, the president wanted me to share a note from his physician ... all results were within normal limits." pic.twitter.com/SmLHZKQlkK— Aaron Rupar (@atrupar) July 17, 2025Earlier in April, President Trump (79) underwent his routine annual physical under the care of Captain Sean Barbabella, his primary physician. Following the exam, Barbabella issued an official memorandum outlining the president's overall health, continuing the administration's effort to maintain transparency regarding his medical status.CHRONIC VENOUS INSUFFICINECYChronic venous insufficiency occurs when the veins in the legs struggle to return blood to the heart. According to the National Library of Medicine's MedlinePlus, this happens when the valves in leg veins weaken or become damaged, allowing blood to pool in the lower limbs rather than flow efficiently upward.While CVI is a progressive condition that tends to worsen over time, early detection and intervention can help manage symptoms and slow its progression. It is especially common in older adults and individuals with risk factors such as prolonged sitting or standing, obesity, or a family history of venous disease.In addition to leg swelling, Leavitt also noted that Trump had bruising on the back of his hand. She attributed this to minor soft tissue irritation caused by frequent handshaking, along with the use of aspirin, which Trump takes as part of a standard cardiovascular prevention regimen.SYMPTOMS OF CVI- CVI can lead to various symptoms, including:- Aching or cramping in the legs- Heaviness or tiredness after long periods of standing- Swelling, particularly around the ankles- Itching or tingling sensations- Skin changes such as thickening, discoloration, or the appearance of varicose veins- In more advanced stages, it may also cause skin ulcers near the ankles or lower legs if left untreated.TREATMENT OF CVIadvertisement- Treatment for chronic venous insufficiency typically begins with conservative measures, especially in early stages. These may include:- Lifestyle adjustments such as regular walking, weight management, and avoiding long periods of immobility- Leg elevation to promote blood flow- Compression stockings, which help improve circulation and reduce swelling- If these symptoms persist or worsen, medical interventions may be necessary. These could include:- Sclerotherapy, which involves injecting a solution into the affected veins- Endovenous ablation therapy, using lasers or radiofrequency to close damaged veins- Vein surgery is performed in more severe cases to remove or bypass the problematic veins- With timely treatment, most people with CVI can reduce their symptoms and prevent complications.- EndsTune InMust Watch
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
2 hours ago
- NDTV
Superbugs Threaten Millions Of Lives And $2 Trillion Loss By 2050, Study Warns
A new study warns that antibiotic-resistant "superbugs" could kill millions more people globally and cost the world economy nearly $2 trillion each year by 2050. The UK government-funded research, conducted by the Center for Global Development think tank, reveals that rising antimicrobial resistance (AMR) could cause annual global GDP losses of around \$1.7 trillion over the next 25 years. Wealthy nations such as the US, UK, and EU are expected to face some of the heaviest economic and health impacts. The findings have sparked criticism over recent international aid cuts. The UK government recently announced the end of funding for the Fleming Fund, which helps combat AMR in low- and middle-income countries. Similarly, the Trump administration confirmed \$9 billion in cuts to its foreign aid budget, while several European nations have also reduced overseas aid spending. Experts say such measures are short-sighted, as tackling AMR globally is vital to protect health systems and economies worldwide. Without urgent action, drug-resistant infections could become one of the biggest health and economic threats of the century. Anthony McDonnell, the lead author of the research and a policy fellow at the Center for Global Development, told The Guardian:"When we conducted our research on the economic impacts of antimicrobial resistance, it was anticipated that resistance rates would continue to follow historical trends. "However, the sudden cuts to Official Development Assistance by the US, which has cut its aid spend by roughly 80%; the UK, which has announced aid cuts from 0.5% to 0.3% of gross national income; and substantial reductions by France, Germany, and others, could drive up resistance rates in line with the most pessimistic scenario in our research. "Even countries that have been successful in keeping AMR rates under control cannot afford to be complacent. Unless AMR programmes are protected from aid cuts, resistance rates across the world will likely increase at a rate in line with the worst-affected countries. "This would result in millions more people dying worldwide, including across G7 nations. Investing in treatment for bacterial infections now will save lives and deliver billions in long-term economic returns." The research calculated the economic and health burden of antibiotic resistance for 122 countries and forecast that in that in this most pessimistic scenario, by 2050, GDP losses in China could reach just under $722bn a year, the US $295.7bn, the EU $187bn, Japan $65.7bn and the UK $58.6bn.
Time of India
4 hours ago
- Time of India
‘Drug companies will have problems': Trump unveils 200% tariff plan to slash soaring drug prices
Trump launches bold plan to cut drug prices, proposing a 200% tariff on imported medicines to reduce foreign dependency and boost US manufacturing. Backed by GOP, the move targets pharma giants to force price drops. With seniors hit hardest by soaring costs, the US faces a drug affordability crisis. Imports have surged to $151B, fueling concerns over supply chain control and healthcare access. Show more Show less
Time of India
10 hours ago
- Time of India
200% tariffs in offing? Trump vows to slash drug prices using import restrictions
Older Americans most at risk Live Events Drug prices already higher than the rest of the world Experts warn Tariff plan could backfire Tariffs could push prices even higher Growing health debt adds to the pressure Rebuilding US drug production will take time (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel U.S. President Donald Trump announced on Tuesday his plan to use import restrictions as a tool to lower drug prices. He stated that foreign suppliers would be pressured to reduce their prices. Speaking at a White House event with Republican lawmakers, Trump addressed the issue of prescription drug costs. He pledged to decrease the amount consumers pay for these medications.'Drug companies will have lot of problems if they don't agree to bring prices down,' he said, making clear he plans to use trade policy as leverage. 'We are going to get drug prices down.' He also stated, 'We will use import restrictions to force foreign suppliers to cut drug prices.'Trump's latest proposal involves a 200 percent tariff on imported pharmaceuticals. His stated aim is to boost domestic drug manufacturing and reduce America's dependence on foreign supply first, he said the plan wouldn't take effect for another year. More recently, he hinted it could begin with a smaller tariff as early as 1 August and ramp up than 60 percent of adults in the US fill at least one prescription each year. That figure climbs sharply with age. According to the Centers for Disease Control and Prevention, nine out of ten Americans over 65 rely on prescription drugs to manage chronic health the high cost of medicine is already keeping many from getting the care they need. Research by the American Association of Retired Persons found that nearly half of adults aged 50 and older have either skipped a prescription because of cost or know someone who United States pays more for prescription drugs than any other country, according to the Department of Health and Human Services. One reason for this is the heavy reliance on imports. Many of the most-used medications in the US are manufactured have more than doubled over the past two decades. In 2006, pharmaceutical imports stood at $65 billion. By 2019, they had jumped to $151 billion. These drugs cover a wide range of treatments, including for arthritis, cancer, schizophrenia, blood clots, osteoporosis and Beschloss of RockCreek Group responded to Trump's proposal, saying, 'That would be potentially disastrous for every person because we need those pharmaceuticals, and it takes those companies a long time to produce them here in the U.S.'Analysts at UBS echoed that concern. They said even a 12-month delay in enforcing the 200 percent tariff offers 'insufficient time' for drug manufacturers to shift production to the US. A realistic timeframe, they believe, is closer to four to five Pharmaceutical Research and Manufacturers of America (PhRMA) commissioned research showing that a 25 percent tariff alone would raise US drug costs by nearly $51 billion. A 200 percent tariff would almost certainly cause even greater impact would be felt most in the generics market. Nearly 80 percent of generic tablets and capsules used in the US come from abroad. Brookings researchers warn that the narrow profit margins on generics mean even modest tariffs could push some drugs out of production altogether. For many patients, these are the only affordable debt in the US continues to rise. Americans collectively owe more than $220 billion in health-related expenses. Fourteen million people owe over $1,000 and three million owe more than $10, burden of higher drug prices will fall hardest on those who are already struggling. Older adults, disabled people and low-income families will likely bear the brunt of the production moved overseas gradually over several decades. Experts say bringing it back cannot be supporters of reshoring agree that the process needs to be managed carefully. A sudden shift could cause immediate drug shortages and price spikes, undermining the very goal of making medicines more accessible and broader aim of building a self-reliant drug supply is shared by many. But most agree the policy path to get there must avoid short-term shocks that could leave millions without the medicines they depend aggressive tariff proposal may play well politically, but the risk it carries for public health is difficult to ignore.
